Skip to content
Research Article Open access CC BY 4.0

Unmasking Type – 1 Diabetes Mellitus Following an Episode of Euglycemic Diabetic Ketoacidosis with SGLT-2 Inhibitor Use: A Case Report

Simant Jha, Nitesh Kumar Singh, Anurag Mahajan

Asian Journal of Research and Reports in Endocrinology · pp. 1–5 · Published 23 May 2020

10.9734/ajrre/2020/v3i111

Abstract

We describe here the case of a patient with Euglycemic DKA in the setting of SGLT-2 inhibitor use, further evaluation of which led to unmasking of Type-1 Diabetes Mellitus. There have been previous case reports where SGLT-2 inhibitor use has led to unmasking of diabetes mellitus type-1 in patients previously diagnosed with diabetes mellitus type-2. We had a 57-year-old female with history of type 2 DM since last 10-12 years on Empagliflozin, Liraglutide, Metformin, Glimepiride and Pioglitazone presented with 5-hour history of shortness of breath which was acute in onset and was not associated with any other complaints. On initial evaluation, random blood sugar was 182 mg/dl. ABG showed high anion gap severe metabolic acidosis and Serum ketones levels were high. She was treated with IV fluids in the form of normal saline and was later switched to dextroseinfusion when her random blood sugar levels fell below 250 mg/dl, Insulin infusion and Potassium correction along with other supportive measures. her symptoms resolved with treatment over 3-4 days. We did a literature review on the topic and present here the pathophysiology, Diagnosis, Management and Prevention of SGLT-2 inhibitor induced Euglycemic DKA.

Euglycemic Dka sglt2 inhibitors empagliflozin euglycemic diabetic ketoacidosis.

References (14)

  1. 1 Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors [DOI]
  2. 2 An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus [DOI]
  3. 3 SGLT2 Inhibitor–associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis [DOI]
  4. 4 Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors [DOI]
  5. 5 Efficacy and safety of sodium glucose co‐transport‐2 inhibitors in type 2 diabetes: a meta‐analysis of randomized clinical trials [DOI]
  6. 6 Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension [DOI]
  7. 7 Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis [DOI]
  8. 8 Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes [DOI]
  9. 9 Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials [DOI]
  10. 10 Empagliflozin in the treatment of type 2 diabetes: evidence to date [DOI]
  11. 11 Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin [DOI]
  12. 12 Euglycemic Diabetic Ketoacidosis in the Setting of SGLT2 Inhibitor Use and Hypertriglyceridemia: A Case Report and Review of Literature [DOI]
  13. 13 Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin [DOI]
  14. 14 Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

15

Page views

0

PDF downloads

1

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.